Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Acquired by Voloridge Investment Management LLC

Voloridge Investment Management LLC lifted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 55.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 164,208 shares of the company's stock after purchasing an additional 58,861 shares during the quarter. Voloridge Investment Management LLC owned about 0.53% of Medpace worth $54,555,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Lindbrook Capital LLC increased its position in Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after purchasing an additional 29 shares during the last quarter. HBK Sorce Advisory LLC increased its holdings in shares of Medpace by 0.5% during the 4th quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company's stock worth $1,789,000 after buying an additional 29 shares during the last quarter. Assetmark Inc. raised its position in shares of Medpace by 20.1% in the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after buying an additional 29 shares during the period. Proficio Capital Partners LLC raised its position in shares of Medpace by 4.1% in the 4th quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock worth $243,000 after buying an additional 29 shares during the period. Finally, Schulhoff & Co. Inc. boosted its holdings in Medpace by 1.2% in the fourth quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company's stock valued at $874,000 after acquiring an additional 30 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Insider Transactions at Medpace

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of the firm's stock in a transaction that occurred on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total transaction of $516,715.84. Following the completion of the sale, the director now owns 2,998 shares of the company's stock, valued at approximately $904,856.36. This trade represents a 36.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 20.30% of the company's stock.

Medpace Stock Up 0.6%

Shares of NASDAQ MEDP traded up $1.86 during trading on Monday, reaching $294.89. 266,217 shares of the stock were exchanged, compared to its average volume of 354,458. The company has a market capitalization of $8.48 billion, a price-to-earnings ratio of 23.35, a price-to-earnings-growth ratio of 3.81 and a beta of 1.55. The business's 50-day moving average price is $301.83 and its 200 day moving average price is $326.59. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.06 by $0.61. The firm had revenue of $558.57 million for the quarter, compared to the consensus estimate of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same quarter in the previous year, the firm posted $3.20 EPS. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on MEDP shares. Leerink Partnrs upgraded Medpace to a "hold" rating in a research note on Monday, March 24th. Truist Financial dropped their target price on shares of Medpace from $333.00 to $300.00 and set a "hold" rating for the company in a research report on Wednesday, April 23rd. William Blair reaffirmed a "market perform" rating on shares of Medpace in a research report on Tuesday, April 22nd. Robert W. Baird decreased their price objective on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a research note on Wednesday, April 23rd. Finally, Mizuho cut their target price on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 9th. Eleven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $349.30.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.